Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Windward Bio | Basel | Series B | $165.0M | 2026-05-04 |
| Angitia Biopharmaceuticals | Westlake Village | Series D | $130.0M | 2026-02-05 |
| Triveni Bio | Watertown | Series C | $65.0M | 2026-06-17 |
| Capstan Therapeutics | San Diego | Series B | $175.0M | 2024-03-20 |
| BlossomHill Therapeutics | San Diego | Series B | $84.0M | 2025-12-10 |
| Convergent Therapeutics | Cambridge | Series A | $40.0M | 2024-09-24 |
| Aspen Neuroscience | San Diego | Series C | $115.0M | 2025-11-20 |
| Sparrow Pharmaceuticals | Portland | Series B | $95.0M | 2025-09-24 |
8 rows of the CSV in 5 of its 18 columns.
- The 46 OrbiMed portfolio companies have raised $7.8B in total.
- 8 of them closed their most recent round in the last 12 months, $917.0M combined.
- The largest of those rounds is Mirador Therapeutics' $250.0M Series B, dated January 2026.
- The most recent is Triveni Bio's $65.0M Series C on 17 June 2026.
- RA Capital Management is an investor in 10 of them, more than any other fund.
- Health care is the most common sector, with 44 companies (96%).
- 37% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (46% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
27 of 46| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown, United States | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
| Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco, United States | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| Angitia Biopharmaceuticals | Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. | Biotech | Westlake Village, United States | Series D | $130.0M | 2026-02-05 | $406.0M | Legend Capital, OrbiMed, Oriza Holdings +1 | 51 to 100 | 2018 |
| Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego, United States | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| BlossomHill Therapeutics | BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. | Biotech | San Diego, United States | Series B | $84.0M | 2025-12-10 | $257.0M | OrbiMed, Cormorant Asset Management, Vivo Capital +2 | 11 to 50 | 2020 |
| Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego, United States | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| Sparrow Pharmaceuticals | Sparrow Pharmaceuticals develops treatments for type 2 diabetes and related metabolic conditions linked to elevated cortisol. | Biotech | Portland, United States | Series B | $95.0M | 2025-09-24 | $156.3M | U.S. Venture Partners, OrbiMed, RiverVest | 1 to 10 | 2013 |
| ENYO Pharma | ENYO Pharma is a biopharmaceutical company based in Lyon, France. | Biotech | Lyon, France | Series C | $7.0M | 2025-06-12 | $108.8M | Bpifrance, OrbiMed, Sofinnova Partners +2 | 11 to 50 | 2014 |
| Sirius Therapeutics | Sirius Therapeutics is a biotechnology company developing RNAi therapies for cardiovascular diseases. | Biotech | San Diego, United States | Series B | $50.0M | 2025-05-09 | $110.0M | OrbiMed, Hankang Capital, Creacion Ventures +1 | 11 to 50 | 2021 |
| Verdiva Bio | Verdiva Bio develops treatments for patients with obesity and cardiometabolic diseases. | Biotech | London, United Kingdom | Series A | $411.0M | 2025-01-09 | $411.0M | General Atlantic, RA Capital Management, OrbiMed +1 | 11 to 50 | 2024 |
| Alentis Therapeutics | Alentis Therapeutics develops novel therapeutics for advanced liver disease and cancer. | Biotech | Allschwil, Switzerland | Series D | $181.4M | 2024-11-12 | Bpifrance, HTGF (High-Tech Gruenderfonds), RA Capital Management +2 | 51 to 100 | 2019 | |
| Convergent Therapeutics | Convergent Therapeutics develops radiopharmaceutical therapies for prostate cancer. | Health care | Cambridge, United States | Series A | $40.0M | 2024-09-24 | $130.0M | RA Capital Management, OrbiMed, Invus | 1 to 10 | 2021 |
| Pathalys Pharma | Pathalys Pharma develops clinical therapeutics for late-stage chronic kidney disease. | Biotech | Raleigh, United States | Series B | $105.0M | 2024-08-20 | $266.0M | KB Investment, OrbiMed, The Carlyle Group +2 | 1 to 10 | 2021 |
| MBX Biosciences | MBX Biosciences is a preclinical biotech company creating therapies for rare endocrine diseases. | Biotech | Carmel, United States | Series C | $63.5M | 2024-08-05 | $238.4M | New Enterprise Associates, RA Capital Management, OrbiMed +2 | 11 to 50 | 2019 |
| Asceneuron | Asceneuron develops therapeutics for orphan tauopathies and Alzheimer's disease. | Biotech | Lausanne, Switzerland | Series C | $100.0M | 2024-07-16 | OrbiMed, Novo Holdings, EQT Life Sciences +1 | 1 to 10 | 2012 | |
| Capstan Therapeutics | Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases. | Biotech | San Diego, United States | Series B | $175.0M | 2024-03-20 | $340.0M | RA Capital Management, OrbiMed, Alexandria Venture Investments +2 | 101 to 250 | 2021 |
| Sionna Therapeutics | Sionna Therapeutics develops small molecule therapies for treating cystic fibrosis. | Biotech | Natick, United States | Series C | $182.0M | 2024-03-06 | $292.0M | RA Capital Management, OrbiMed, T. Rowe Price +2 | 11 to 50 | 2018 |
| Koya Medical | Koya Medical develops treatments for lymphedema and venous diseases. | Biotech | Oakland, United States | Series C | $30.0M | 2023-11-15 | $70.2M | National Science Foundation, MedTech Innovator, OrbiMed +2 | 101 to 250 | 2018 |
| Rampart Bioscience | Rampart Bioscience develops gene medicines for long-lasting treatment of diverse diseases. | Biotech | La Jolla, United States | Series A | $85.0M | 2023-10-24 | $85.0M | RA Capital Management, OrbiMed, Forbion Capital Partners +1 | 11 to 50 | 2019 |
| Edge Medical Robotics | Edge Medical Robotics designs, develops, and commercializes surgical robot platforms and medical devices. | Hardware | Shenzhen, China | Series C | $200.0M | 2021-11-05 | $308.0M | Temasek, Mirae Asset Venture Investment, OrbiMed +1 | 11 to 50 | 2017 |
| MobileODT | MobileODT develops AI-based medical devices for cervical cancer screening. | Artificial intelligence | Tel Aviv, Israel | Series C | $4.0M | 2020-08-12 | MedTech Innovator, OrbiMed, VU Venture Partners +2 | 11 to 50 | 2012 | |
| Therachon | Therachon is a global biotechnology company developing medicines for rare genetic diseases. | Biotech | Basel, Switzerland | Series B | $60.0M | 2018-08-09 | $100.0M | Bpifrance, New Enterprise Associates, OrbiMed +2 | 1 to 10 | 2014 |
| Nutrinia | Nutrinia develops therapies for patients with intestinal failure. | Biotech | Ramat Gan, Israel | Series D | $30.0M | 2016-08-18 | OrbiMed, Pontifax, WuXi Healthcare Ventures +2 | 11 to 50 | 2003 | |
| OmniGuide | OmniGuide develops and commercializes minimally invasive surgical tools as a medical device company. | Hardware | Lexington, United States | Series F | $15.0M | 2013-09-26 | $129.8M | OrbiMed, 3i Group, Alliance Technology Ventures +2 | 251 to 500 | 2000 |
| Treato | Treato collects patient-written health experiences from blogs and forums to reveal patient opinions. | Artificial intelligence | Or Yehuda, Israel | Series B | $14.5M | 2013-04-23 | Western Technology Investment, OrbiMed, REV +1 | 11 to 50 | 2008 | |
| Rejuvenon | Rejuvenon is a biopharmaceutical company developing and commercializing compounds for treating oncologic diseases. | Biotech | The Woodlands, United States | Series B | $37.0M | 2004-06-23 | $49.0M | OrbiMed, Boston Millennia Partners, Prospect Venture Partners +1 | 1 to 10 | 2000 |
Table 1. OrbiMed portfolio companies: the 27 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 46.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego, United States | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| 2 | Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| 3 | Angitia Biopharmaceuticals | Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. | Biotech | Westlake Village, United States | Series D | $130.0M | 2026-02-05 | $406.0M | Legend Capital, OrbiMed, Oriza Holdings +1 | 51 to 100 | 2018 |
| 4 | Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego, United States | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| 5 | Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco, United States | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| 6 | BlossomHill Therapeutics | BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. | Biotech | San Diego, United States | Series B | $84.0M | 2025-12-10 | $257.0M | OrbiMed, Cormorant Asset Management, Vivo Capital +2 | 11 to 50 | 2020 |
| 7 | Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown, United States | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
Table 2. OrbiMed portfolio companies: the 7 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Management | Startup incubator | Boston, United States | 10 | 22% | ||
| 2 | Invus | Private equity firm | New York, United States | 5 | 11% | 1 | Triveni Bio |
| 3 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 4 | 9% | 2 | Windward Bio, Terremoto Biosciences |
| 4 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 4 | 9% | 2 | Triveni Bio, Aspen Neuroscience |
| 5 | Bpifrance | Government investment office | Maisons-alfort, France | 4 | 9% | ||
| 6 | Blue Owl | Private equity firm | New York, United States | 3 | 7% | 2 | Windward Bio, Mirador Therapeutics |
| 7 | Morningside | Private equity firm | Newton, United States | 3 | 7% | 1 | Angitia Biopharmaceuticals |
| 8 | T. Rowe Price | Private equity firm | Baltimore, United States | 3 | 7% | ||
| 9 | Fidelity | Investment bank | Boston, United States | 3 | 7% | 1 | Mirador Therapeutics |
| 10 | Versant Ventures | Venture capital firm | Menlo Park, United States | 3 | 7% | ||
| 11 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 4% | 1 | Windward Bio |
| 12 | Cormorant Asset Management | Hedge fund | Boston, United States | 2 | 4% | 2 | Triveni Bio, BlossomHill Therapeutics |
| 13 | Wellington Management | Private equity firm | Boston, United States | 2 | 4% | ||
| 14 | New Enterprise Associates | Venture capital firm | Menlo Park, United States | 2 | 4% | ||
| 15 | Lightspeed Venture Partners | Venture capital firm | Menlo Park, United States | 2 | 4% |
Table 3. OrbiMed portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 44 | 96% | $7.4B |
| Biotech | 38 | 83% | $6.8B |
| Software | 11 | 24% | $735.2M |
| Artificial intelligence | 4 | 9% | $169.3M |
| Hardware | 2 | 4% | $437.8M |
Table 4. OrbiMed portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. OrbiMed portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 30 | 65% |
| Switzerland | 4 | 9% |
| Israel | 4 | 9% |
| China | 4 | 9% |
| France | 2 | 4% |
| United Kingdom | 1 | 2% |
| Germany | 1 | 2% |
Table 6. OrbiMed portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. OrbiMed portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| June 2026 | 1 | 12% | $65.0M |
| May 2026 | 1 | 12% | $165.0M |
| April 2026 | 1 | 12% | $108.0M |
| March 2026 | 1 | 12% | |
| February 2026 | 1 | 12% | $130.0M |
| January 2026 | 1 | 12% | $250.0M |
| December 2025 | 1 | 12% | $84.0M |
| November 2025 | 1 | 12% | $115.0M |
Table 8. OrbiMed portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 6 | 13% | $718.0M |
| 2025 | 7 | 15% | $822.0M |
| 2024 | 14 | 30% | $1.5B |
| 2023 | 5 | 11% | $315.5M |
| 2022 | 1 | 2% | $63.0M |
| 2021 | 2 | 4% | $298.1M |
Table 9. OrbiMed portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 3 | 7% |
| 2020 to 2022 | 14 | 30% |
| 2015 to 2019 | 13 | 28% |
| 2010 to 2014 | 6 | 13% |
| Before 2010 | 10 | 22% |
Table 10. OrbiMed portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 9 | 20% |
| 11 to 50 | 21 | 46% |
| 51 to 100 | 7 | 15% |
| 101 to 250 | 7 | 15% |
| 251 to 500 | 1 | 2% |
| 501 to 1,000 | 1 | 2% |
Table 11. OrbiMed portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when OrbiMed is recorded as one of its investors. On 16 November 2026 that is 46 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 27 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 46 rows: 3 have no round amount, 0 no city and 5 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many OrbiMed portfolio companies are on the list?
- 46, in the file dated 16 November 2026. 8 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 46 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.